Acorda Asks Justices To Abolish 'Blocking Patent' Doctrine
Acorda Therapeutics has asked the U.S. Supreme Court to abolish the "blocking patent" doctrine that the Federal Circuit used to invalidate four of its patents on its multiple sclerosis drug Ampyra,...To view the full article, register now.
Already a subscriber? Click here to view full article